Digostics - Lab quality diabetes testing, at home.

Timely Diabetes Care Demands a New Approach to Testing

50% of adults living with diabetes remain undiagnosed.

Given the significant population health implications of missed or delayed detection, an immediate step-change is required in how we test for diabetes.

Digostics offers the world's first and only alternative to in-clinic oral glucose tolerance testing (OGTT) by enabling this crucial diabetes test to be performed at home.

Simplified testing. Increased patient throughput. Better outcomes.

The Future of Diabetes Detection, Today

Revolutionising Diabetes Testing

The OGTT remains the gold standard in diabetes testing. However, the test takes over two hours to perform. Furthermore, the complexity involved means it is only offered in clinics.

The inconvenience of clinic OGTT for patients and the provisioning challenges posed for healthcare professionals are significant reasons why total patient testing volumes consistently fall short of targets in standard of care.

It’s time for something different.

GTT@home is a revolutionary new OGTT home-testing service from Digostics comprised of a simple-to-use device that enables diabetes testing on a date and at a location of the patient's choosing.

Let's take the test to the patient.

No travel to clinic
Takes less time
No out-of-pocket expenses
Minimal disruption to daily routine
Test on day of choice
Relaxed test environment
Faster results
Earlier access to treatment

Speed up diagnosis
Earlier intervention opportunities
Increased testing capacity
Minimal disruption to daily routine
Meet targets in standards of care
Lower overall cost of test
Optimisation of clinic resources
Reduced administration
Covid-19 mitigation measure
Reduced pressure on midwifery

Easier Diabetes Testing for Everyone

Improving Access to OGTT

Everyone should have timely and convenient access to OGTT.

And yet, late or missed tests are common as in-clinic OGTT becomes increasingly difficult to schedule, deliver and attend.

GTT@home empowers healthcare providers to offer OGTT to those who need it, when they need it. And without concern as to how the associated test workload will be managed.

Similarly, patients get to test safely from home, with minimal disruption to daily routines and with the ability to have their results sent immediately to those responsible for their care.

A win-win for patients and healthcare professionals alike.

Streamlining the OGTT Test Workflow

Greater testing capacity. Faster diagnoses.

GTT@home ensures more patients can be easily tested, on time.

It provides clinic-equivalent test performance. But significantly, without any of the staffing overheads, risks of sample degradation and laboratory delays that frequently impact clinic testing capacity.

By eliminating in-clinic tests, GTT@home enables more testing, faster results, and where warranted, an unparalleled opportunity for early clinical intervention.

Solution Features:

Proven equivalence to in-clinic OGTT
Universal ease of use without training
Preferred by patients
NFC technology for smartphone reading
Supports HL7 v2 messaging
HL7 FHIR compliant
Cyber security accreditation
UK and European marketing authorisation

GTT@home in Practice

Poster: GTT@home - Home Oral Glucose Test -

An Alternative to Clinic Visits

Download our latest study demonstrating GTT@home's equivalent performance to in-clinic OGTT.

"GTT@home has an excellent correlation and low bias compared to a reference laboratory glucose analyser, with an excellent agreement in categorisation of glucose tolerance."

Professor Steve Luzio

Swansea University

"GTT@home improved uptake of testing in a critical patient group from 52% to 82% in a single offering."

Dr Catherine Peters

Great Ormond Street Hospital

"Detecting gestational diabetes is a national and global priority. OGTT home-testing would be a great boost to the identification and management of gestational diabetes."

Sir George Alberti

Newcastle University

"We, and several of our leading clinical colleagues around the world, have the view that GTT@home could transform screening for glucose intolerance in T1D and become an important tool in clinical studies and in standards of care "

Dr Frank Martin

Juvenile Diabetes Research Foundation

"GTT@home offers a valuable addition to the diagnostic methods for prediabetes and diabetes."

Professor Jaakko Tuomilehto

University of Helsinki

"OGTT are an important but inaccessible test. However, Digostics’ OGTT home-testing approach could change this by making the detection of prediabetes, GDM and diabetes more convenient and easier to perform. This has exciting implications for both developed and underserved markets."

Professor Stephen Colagiuri

University of Sydney

About Digostics

Lab quality diabetes testing, at home.

Far too many people, in all geographies, are living with undiagnosed diabetes.

Digostics' mission is to enable healthcare providers to detect everyone with diabetes, and those at risk of developing diabetes, by eliminating the common barriers that inhibit testing and prevent the timely return of accurate diagnoses.

Digostics is proud to offer GTT@home - the most accessible and scalable way for clinical teams to realise their diabetes testing objectives.

Lab quality diabetes testing, at home.

Timely Diabetes Care Demands a New Approach to Testing

"Diabetes is Spiralling Out of Control"

International Diabetes Federation, 2022

Fortunately, Digostics is here to help.

The Future of Diabetes Detection, Today

Revolutionising Diabetes Testing

Let's take the test to the patient.

Patient Benefits

Clinical Benefits

Easier Diabetes Testing for Everyone

Improving Access to OGTT

Streamlining the OGTT Test Workflow

Greater testing capacity. Faster diagnoses.

University Hospital Southampton

UHS and Digostics partner on a world-first project designed to improve screening for gestational diabetes.

One Test, So Many Applications

Gestational Diabetes

Type One

Type Two

Prediabetes

Cystic Fibrosis

Clinical Trials

and more...

"GTT@home has an excellent correlation and low bias compared to a reference laboratory glucose analyser, with an excellent agreement in categorisation of glucose tolerance."

"GTT@home improved uptake of testing in a critical patient group from 52% to 82% in a single offering."

"Detecting gestational diabetes is a national and global priority. OGTT home-testing would be a great boost to the identification and management of gestational diabetes."

"We, and several of our leading clinical colleagues around the world, have the view that GTT@home could transform screening for glucose intolerance in T1D and become an important tool in clinical studies and in standards of care "

"GTT@home offers a valuable addition to the diagnostic methods for prediabetes and diabetes."

"OGTT are an important but inaccessible test. However, Digostics’ OGTT home-testing approach could change this by making the detection of prediabetes, GDM and diabetes more convenient and easier to perform. This has exciting implications for both developed and underserved markets."

About Digostics

Lab quality diabetes testing, at home.

Can Digostics Help?